An off-the-shelf bispecific antibody developed by Roche induced high and durable response rates in patients with a slow-growing type of lymphoma — study results that are likely to secure the treatment’s approval and help it rival a custom-made CAR-T therapy.
The study enrolled 90 patients, all of whom were given intravenous infusions of the Roche drug, called mosunetuzumab. Complete remissions were reported in 54 patients, or 60%, meaning their disease was undetectable. The overall response rate was 80% with median duration of response lasting nearly 23 months.
The enrolled patients were diagnosed with follicular lymphoma, a slow-growing form of non-Hodgkin’s lymphoma. To enter the study, the patients had to have relapsed disease after two or more previous therapies.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
